BioStock contacted CEO Andreas Gerward who shared his thoughts and provided further details about the recent findings and what they mean for the future of herniated disc treatments. Link: https://t.co/ZeYWlZbxeJ #discherniation #backpain

New insights from Stayble! Data from Stayble's Phase IIb study strengthens the foundation of our treatment for herniated discs. Discover more in the full press release: https://t.co/oXg1LwKiRj #herniateddiscs #backpain

Vi har intervjuat Stayble Therapeutics VD Andreas Gerward i samband med top-line data från bolagets fas 2b-studie mot degenerativ disksjukdom. Vi diskuterar bland annat resultatet och hur vägen framåt ser ut. $STABL Länk: https://t.co/hghS1RT25y

Stayble Therapeutics shifts focus to phase Ib study in disc herniation! Following recent events, our CEO, Andreas Gerward, met with BioStock and shared his insights about the future plans for Stayble. Link: https://t.co/2FfOgPnzZc #backpain #clinicaltrial #herniateddisc

The interim report for the third quarter is now available! Stayble Therapeutics has published its interim report for the third quarter of 2023. Explore the full report by following the link: https://t.co/2PVYeO0D94

Stayble is on track to present top-line data from the Phase IIb study of STA363. The anticipated results are set to be shared within the next month, with a target of November or early December. https://t.co/nK4WxIjGq7 #backpain #degenerativediscdisease #healthcare

Vi har intervjuat @Stayble VD Andreas Gerward avseende samarbetet med Ferghana Partners. Vi diskuterar bland annat Ferghanas styrkor, fokus och incitament samt historik av transaktioner. Länk till intervjun: https://t.co/pXz272J2ZC $STABL

Last week, Andreas represented Stayble at the Redeye Investor Forum. Follow the link to view the full presentation: https://t.co/hwLdtEDhoW @redeye_ #backpain #degenerativediscdisease #herniateddisc

Stayble is excited to be part of the Redeye Investor Forum today. Join us for a live broadcast where we, along with three other companies, will be presenting for 12 minutes, followed by an 8-minute Q&A session moderated by expert analysts. Link: https://t.co/5KspzuHcab

We are pleased to share that Stayble has initiated a collaboration with transaction advisor Ferghana Partners to support our international partnering activities. Link to full press release: https://t.co/mpWwzloRfG #backpain #clinicaltrial #degenerativediscdisease

What makes Stayble Therapeutics unique? Our CEO, Andreas Gerward, addressed this at Financial Stockholm's investor meeting this Monday and provided the latest updates on our mission to develop innovative treatments for chronic back pain. Link: https://t.co/J5SjVZQns1

Recently, we reported that the last patient had completed all visits in our Phase IIb study. We are on course to unveil our top-line results in Q4 of 2023 - an exciting time for patients with degenerative disc disease worldwide. https://t.co/T4Tyga5t3J #backpain #toplineresults

New interview with our CEO! Andreas recently sat down with @kalqyl for a short interview. Dive into the conversation to discover Stayble's latest progress and get a glimpse of the future ahead. Link: https://t.co/k0zX0OVTgA #backpain #clinicaltrial #degenerativediscdisease

Stayble is pleased to announce that the The Last Patient Last Visit milestone has been achieved! The next phase involves data verification and quality controls, with results expected in Q4 2023. https://t.co/Hiuyx5rww9 #backpain #clinicaltrial #degenerativediscdisease

Last week, Stayble successfully enrolled and treated the first patient in the company’s clinical Phase Ib study for herniated discs using STA363. For more insights from CEO Andreas Gerward, follow the link. 👉 https://t.co/OJD7CVwibQ #backpain #clinicaltrial #herniateddisc

Progress in our Phase 1b study! Stayble is pleased to announce important developments in our clinical research. We successfully enrolled the first patient in the Phase 1b clinical study of STA363, which focuses on the treatment of herniated discs. https://t.co/2Ahsra2BUJ

Stayble Therapeutics is pleased to unveil its half-year report for 2023, highlighting significant achievements in the second quarter. Explore the full report by following the link: https://t.co/KbE12SZe8q #backpain #clinicaltrial #degenerativediscdisease #herniateddiscs

Aktiespararna has just released an updated analysis, providing valuable insights into Stayble Therapeutics' recent developments. For our Swedish readers, you can read the full analysis here: https://t.co/dTKNSNItwK #Clinicaltrial #Backpain #Degenerativediscdisease

Access the complete press release for further information: https://t.co/XL0nujcAyM

Exciting Update! Stayble is excited to share that approximately 90% of patients have completed their 12-month follow-up! With a continued low dropout rate, we are on track to present top-line data from our study in Q4 2023. #Clinicaltrial #Backpain #Degenerativediscdisease